Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Revenue of $3.0 billion for Q1 2026, up 7.82% year-over-year from $2.8 billion in Q1 2025, and down 6.37% quarter-over-quarter from $3.2 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Revenue history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.
- In Q1 2026, Revenue rose 7.82% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $12.2 billion (up 10.08% YoY), while the FY2025 annual figure was $12.0 billion, up 8.9% from the prior year.
- Revenue for Q1 2026 stood at $3.0 billion, down from $3.2 billion in the prior quarter.
- The five-year high for Revenue was $3.2 billion in Q4 2025, with the low at $2.1 billion in Q1 2022.
- The 5-year median for Revenue is $2.6 billion (2024), against an average of $2.6 billion.
- The sharpest annual moves came in 2022 and 2025: Revenue climbed 22.46% in 2022, then advanced 2.96% in 2025.
- Vertex Pharmaceuticals' Revenue stood at $2.3 billion in 2022, then gained by 9.34% to $2.5 billion in 2023, then advanced by 15.66% to $2.9 billion in 2024, then advanced by 9.55% to $3.2 billion in 2025, then fell by 6.37% to $3.0 billion in 2026.
- Business Quant data shows VRTX's Revenue at $3.0 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.33 Bn |
| Mar 31, 2026 | 2.99 Bn |
| Dec 31, 2025 | 3.19 Bn |
| Sep 30, 2025 | 3.08 Bn |
| Jun 30, 2025 | 2.96 Bn |
| Mar 31, 2025 | 2.77 Bn |
| Dec 31, 2024 | 2.91 Bn |
| Sep 30, 2024 | 2.77 Bn |
| Jun 30, 2024 | 2.65 Bn |
| Mar 31, 2024 | 2.69 Bn |
| Dec 31, 2023 | 2.52 Bn |
| Sep 30, 2023 | 2.48 Bn |
| Jun 30, 2023 | 2.49 Bn |
| Mar 31, 2023 | 2.37 Bn |
| Dec 31, 2022 | 2.30 Bn |
| Sep 30, 2022 | 2.33 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 2.10 Bn |
| Dec 31, 2021 | 2.07 Bn |
| Sep 30, 2021 | 1.98 Bn |